Pulnovo Medical announces first enrollment in Portugal for global clinical study of PADN technology

image credit- shutterstock

Pulnovo Medical is pleased to announce the successful initiation and first two patients enrollment for its global multicenter clinical study exploring the percutaneous pulmonary artery denervation (PADN) treatment for pulmonary hypertension associated with left heart disease. This took place at Centro Hospitalar Universitário de Lisboa Central - Hospital de Santa Marta in Portugal.

Under the guidance of Professor Hang Zhang from Nanjing Medical University Affiliated Nanjing Hospital, Prof. Ruben Ramos and his team successfully performed the PADN procedure on two patients. The products' comprehensive design and high-precision algorithm control significantly ensured stable energy output and effective surgical results.

Jessie Lian，Pulnovo Medical's CEO said, "The PADN global multicenter clinical study is one of our key projects dedicated to innovative treatment technologies in the cardiovascular field. As an emerging treatment, PADN has enormous potential and prospects. The post-operative results of the first overseas application of PADN reflect the academic borderlessness of the moment. In the future, we will continue to firmly advance our global business, steadily promoting the teaching and learning of PADN technology. "